Desuden var induration og smerte på infusionsstedet almindelige bivirkninger i en bioækvivalensundersøgelse, hvor 66 forsøgspersoner fik 115 mg fosaprepitant intravenøst.
In addition, infusion site induration and infusion site pain were common adverse reactions in a bioequivalence study in which 66 subjects were dosed with 115 mg of fosaprepitant intravenously.